A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
Latest Information Update: 08 May 2025
At a glance
- Drugs Povorcitinib (Primary)
- Indications Prurigo nodularis
- Focus Therapeutic Use
- Acronyms STOP-PN2
- Sponsors Incyte Corporation
Most Recent Events
- 20 Sep 2024 Status changed from not yet recruiting to recruiting.
- 29 Jul 2024 New trial record